Tivic Health enters into agreement with NIAID

Tivic Health (TIVC) Systems announced it has entered into an agreement with the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, to sponsor and conduct a series of preclinical studies evaluating Entolimod for gastrointestinal acute radiation syndrome, GI-ARS. The program is expected to support Tivic’s development strategy for Entolimod as a medical countermeasure for acute radiation syndrome. Under the agreement, NIAID will fund and conduct GI-ARS studies, the first of which will be performed at the Armed Forces Radiobiology Research Institute